Emcure Pharmaceuticals Share Price Rises Following Kotak Initiation of Coverage
Emcure Pharmaceuticals Stock Performance
Emcure Pharmaceuticals share price jumped over 5% to hit a fresh 52-week high on Wednesday after domestic brokerage firm Kotak Institutional Equities initiated coverage on the stock with a bullish view. Emcure Pharma shares spiked as much as 5.80% to a high of ₹1,577.50 apiece on the BSE. Kotak has assigned an ‘Add’ rating to Emcure Pharmaceuticals shares with a target price of ₹1,655 per share, implying an upside potential of 11% from Tuesday’s closing price.
Kotak’s Analysis of Emcure Pharmaceuticals
Kotak Equities evaluated that Emcure is one of the few Indian pharma majors with no direct US generics exposure, thereby lending greater earnings stability. Backed by its R&D prowess, Emcure has built a complex portfolio across India, Canada, Europe, and emerging markets (EMs). The share price target by Kotak is based on 30X September 2026 EPS estimates, which reflects a ~20% discount to the P/E multiples assigned to Mankind Pharma, Torrent Pharmaceuticals, and JB Chemicals and Pharmaceuticals.
- Industry-leading return ratios
- Expected Emcure to trade at a discount compared to domestic-focused companies
Despite its stable fundamentals, current valuations of ~16X FY2026E EV/EBITDA and ~30X FY2026E P/E are yet to fully encapsulate the growth potential of the business. Kotak Equities believes the ~12% to 15% 10-year overall sales/EBITDA CAGRs capture the company's potential success in the domestic and international segments.
Growth and Risks Ahead
Led by healthy organic growth, in-licensing deals with Sanofi, and consolidation of Mantra, Kotak Equities expects Emcure Pharma to report a 14% overall sales CAGR over FY2024-27E. However, risks include further repercussions from US drug price-fixing cases and any potential litigation.
Emcure Pharmaceuticals Share Price History
Emcure Pharmaceuticals shares were listed on Indian stock exchanges on July 10 with a strong premium of over 31% at ₹1,325.05 apiece against the issue price of ₹1,008 per share. Emcure Pharmaceuticals stock is up more than 19% from its listing price and over 56% from its IPO price.
As of 2:40 PM, Emcure Pharma shares were trading 2.51% higher at ₹1,528.40 apiece on the BSE.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.